| Vepa Llc | |
|
2655 W National Rd Springfield OH 45504-3617 | |
| (937) 430-1230 | |
| Not Available |
| Full Name | Vepa Llc |
|---|---|
| Speciality | General Practice |
| Location | 2655 W National Rd, Springfield, Ohio |
| Authorized Official Name and Position | Parminder Modgil (OWNER) |
| Authorized Official Contact | 9374301230 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Vepa Llc 1140 Charter Pl Centerville OH 45458-3943 Ph: (937) 430-1230 | Vepa Llc 2655 W National Rd Springfield OH 45504-3617 Ph: (937) 430-1230 |
| NPI Number | 1124475504 |
|---|---|
| Provider Enumeration Date | 05/16/2016 |
| Last Update Date | 05/16/2016 |
| Medicare PECOS PAC ID | 0648561761 |
|---|---|
| Medicare Enrollment ID | O20160621001896 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124475504 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 201613003416 (Ohio) | Primary |
| Provider Name | Parminder K Modgil |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1528166816 PECOS PAC ID: 0446257323 Enrollment ID: I20061107000463 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Provider Name | Arshad Ali Shah |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1578583605 PECOS PAC ID: 9436154945 Enrollment ID: I20080409000290 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Provider Name | Sherri Lynn Underwood |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225546823 PECOS PAC ID: 4587913736 Enrollment ID: I20180821001837 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Provider Name | Cheryl Minney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407355696 PECOS PAC ID: 4688003916 Enrollment ID: I20200407002182 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Provider Name | Melissa A Williamson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972075471 PECOS PAC ID: 0749610434 Enrollment ID: I20200421000448 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Provider Name | Kimberly Ann Mccutcheon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750032520 PECOS PAC ID: 0547656266 Enrollment ID: I20220406001289 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Provider Name | Heather D Ferguson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750920617 PECOS PAC ID: 0446633168 Enrollment ID: I20220812002551 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Provider Name | Jodie Lynn Beard |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1104956259 PECOS PAC ID: 0244614287 Enrollment ID: I20220825001069 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
| Provider Name | Shayla A Nayles |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568118081 PECOS PAC ID: 7517332463 Enrollment ID: I20230407000614 |
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
News Archive
Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.
Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Cleveland Medical Devices has announced that it has been awarded $2.3 M in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
› Verified 4 days ago
Jyothi Puram, M.d., Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1176 E Home Rd, Springfield, OH 45503 Phone: 937-342-9861 Fax: 380-203-1298 | |
Rocking Horse Center Chiropractic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 651 S Limestone St, Springfield, OH 45505 Phone: 937-324-1111 Fax: 937-525-4543 | |
Ajaz Umerani, M.d. Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2121 E High St, Springfield, OH 45505 Phone: 937-325-3830 Fax: 937-325-3780 | |
Usacs Integrated Acute Care Services Of Ohio, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 100 Medical Center Dr, Springfield, OH 45504 Phone: 330-994-4409 | |
Springfield Neurosurgical Associates Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2200 N Limestone St, Suite 100, Springfield, OH 45503 Phone: 937-328-8018 Fax: 937-328-6203 | |
Rodney Family Practice Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2057 S Limestone St, Springfield, OH 45505 Phone: 937-323-4003 Fax: 937-323-4023 | |
Kenneth L. Reed, D.o., Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2330 E High St, Suite B, Springfield, OH 45505 Phone: 937-325-3696 Fax: 937-325-3713 |